M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia

Phase 1

Recruiting

Conditions: COVID-19 Infection
COVID-19-Associated Acute Respiratory Distress Syndrome
Hematopoietic and Lymphoid Cell Neoplasm
Malignant Solid Neoplasm
Symptomatic COVID-19 Infection Laboratory-Confirmed

Interventions: Other: Best Practice
Biological: Mesenchymal Stem Cell

First Posted Date: 2020-09-25

Last Posted Date: 2024-08-29

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 70

Registration Number: NCT04565665

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Safety of MRI Compatible Hardware for MRI-based Image Guidance During Spine Surgery

Early Phase 1

Terminated

Conditions: Thoracic Spine Neoplasm

Interventions: Device: Magnetic Resonance Imaging
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2020-09-24

Last Posted Date: 2022-07-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 16

Registration Number: NCT04563806

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Bintrafusp Alfa Before Surgery for the Treatment of Untreated Resectable Non-small Cell Lung Cancer

Phase 2

Terminated

Conditions: Stage I Lung Cancer AJCC v8
Stage IA1 Lung Cancer AJCC v8
Stage IA2 Lung Cancer AJCC v8
Stage IA3 Lung Cancer AJCC v8
Stage IIIA Lung Cancer AJCC v8
Resectable Lung Non-Small Cell Carcinoma
Stage IIA Lung Cancer AJCC v8
Stage IIIB Lung Cancer AJCC v8
Stage IB Lung Cancer AJCC v8
Stage II Lung Cancer AJCC v8

Interventions: Drug: Bintrafusp Alfa
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2020-09-23

Last Posted Date: 2022-07-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 2

Registration Number: NCT04560686

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy

Phase 2

Recruiting

Conditions: Chemotherapy-Induced Peripheral Neuropathy
Hematopoietic and Lymphoid Cell Neoplasm
Malignant Solid Neoplasm

Interventions: Drug: Duloxetine
Behavioral: Neurofeedback
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2020-09-23

Last Posted Date: 2024-07-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 380

Registration Number: NCT04560673

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Harris Health System (LBJ), Houston, Texas, United States

Acupuncture for the Management of Postoperative Pain in Patients With Pancreatic or Colorectal Cancer Undergoing Surgery

Not Applicable

Active, not recruiting

Conditions: Resectable Colorectal Carcinoma
Resectable Digestive System Carcinoma
Resectable Pancreatic Carcinoma

Interventions: Procedure: Acupuncture Therapy
Other: Best Practice
Other: Questionnaire Administration

First Posted Date: 2020-09-23

Last Posted Date: 2024-10-29

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 70

Registration Number: NCT04560712

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Major Complication Rate in Cancer Patients With Neutropenic Fever Potentially Eligible for a Hospital at Home Program

Recruiting

Conditions: Malignant Solid Neoplasm
Hematopoietic and Lymphoid Cell Neoplasm

Interventions: Other: Medical Chart Review

First Posted Date: 2020-09-22

Last Posted Date: 2024-03-06

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 126

Registration Number: NCT04557709

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer

Phase 1

Active, not recruiting

Conditions: Head and Neck Squamous Cell Carcinoma
Malignant Solid Neoplasm

Interventions: Drug: Alisertib
Biological: Pembrolizumab

First Posted Date: 2020-09-21

Last Posted Date: 2024-12-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 24

Registration Number: NCT04555837

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Peposertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma

Phase 1

Recruiting

Conditions: Glioblastoma
Gliosarcoma

Interventions: Drug: Peposertib
Radiation: Radiation Therapy
Procedure: Resection
Drug: Temozolomide

First Posted Date: 2020-09-18

Last Posted Date: 2024-11-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 29

Registration Number: NCT04555577

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Seizure Control As a New Metric in Assessing Efficacy of Tumor Treatment in Patients with Low Grade Glioma

Active, not recruiting

Conditions: Seizure Disorder
Low Grade Glioma
Brain Neoplasm

Interventions: Other: Survey Administration

First Posted Date: 2020-09-17

Last Posted Date: 2024-11-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 100

Registration Number: NCT04553757

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Identification of Surgical Management of Lymph Node Basins and Surgical Practice Patterns Among Sarcoma Surgeons

Withdrawn

Conditions: Soft Tissue Sarcoma
Lymph Node Cancer

Interventions: Other: Survey Administration

First Posted Date: 2020-09-17

Last Posted Date: 2024-02-29

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT04553744

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy